

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/760,091
				Filing Date	January 16, 2004
				First Named Inventor	Thomas L. CANTOR
				Art Unit	1641
				Examiner Name	C. Cheu
Sheet	1	of	3	Attorney Docket Number	532212000624

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/C.C./	1.	US-6,548,066	04/2003	Michaeli et al.	
↓	2.	US-6,689,566-C1	07/2009	Cantor et al.	
	3.	US-6,756,480	06/2004	Kostenuik et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

Examiner Signature	/Changhwa Cheu/	Date Considered	01/13/2010
---------------------------	-----------------	------------------------	------------

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/C.C./	4.	U.S. Patent Application 10/956,760, filed by Cantor on October 1, 2004			
	5.	Restriction Requirement from 10/956,760, mailed on March 29, 2007			
	6.	Response to Restriction Requirement from 10/956,760, filed on April 23, 2007			
	7.	Non-Final Office Action from 10/956,760, mailed on July 16, 2007			
	8.	Amendment in Response to Non-Final Office Action from 10/956,760, filed on October 16, 2007			
	9.	Office Communication from 10/956,760, mailed on April 2, 2008			
	10.	Amendment in Response to Office Communication from 10/956,760, filed April 29, 2008			
	11.	Decision Returning Improper Papers from Control No. 90/007,685 and 90/007,732, mailed on April 21, 2009			
	12.	Petition Decision from 10/641,780, mailed on May 8, 2009			
	13.	Notice of Non-Compliant Information Disclosure Statement from 10/945,608, mailed on May 7, 2009			
	14.	Petition Decision from 10/945,608, mailed on May 8, 2009			
	15.	Opposition Decision (with English summary) from Opposition against JP patent No. 3457004, dated September 8, 2008			
	16.	Revised Order for Summary Judgment of Non-Infringement, filed April 23, 2009			
↓	17.	Court Docket From PACER for Scantibodies Laboratory, Inc. v. Immutopics, Inc., the United			

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/760,091
			Filing Date	January 16, 2004
			First Named Inventor	Thomas L. CANTOR
			Art Unit	1641
			Examiner Name	C. Cheu
			Attorney Docket Number	532212000624
Sheet	2	of	3	

/C.C./	States District Court for the Central District of California (Western Division), Case No. CV 04-08871 MRP (MANx), docket accessed June 11, 2009	
18.	Order – Bd.R. 104(a), filed June 9, 2009, Patent Interference No. 105,575 (MPT)	
19.	Non-Final Office Action from 11/799,726, mailed on June 11, 2009	
20.	BARBIER et al., J. Med. Chem. (1997) 40:1373-1380	
21.	NUSSBAUM et al., J. Biol. Chem. (1980) 255:10183-10187	
22.	JAMESON and WOLF, The Antigenic Index: A Novel Algorithm for Predicting Antigenic Determinants, CABIOS 4, 1988, pages 181-186	
23.	Communication pursuant to Article 94(3) EPC for European Patent Application No. 06008181.7, mailed on February 9, 2009, 1 page	
24.	Response to Communication pursuant to Article 94(3) EPC for European Patent Application No. 06008181.7, dated June 18, 2009, 20 pages	
25.	Zahradnik Notification of Court Decision in Related Litigation, filed June 16, 2009, from Patent Interference No. 105,575 (MPT)	
26.	Letter from Leonard Svensson regarding Patent Interference No. 105,575 (MPT), dated June 17, 2009	
27.	Restriction Requirement for U.S. Patent Application Serial No. 11/894,367, mailed on June 12, 2009, 7 pages	
28.	Declaration of Brian W. Kasell in Support of Plaintiff's Opposition to Immotopics' Motion to Declare Case Exceptional Pursuant to 35 U.S.C. § 285 and for Leave to Submit Detailed Description of Attorney Fees, filed on June 15, 2009	
29.	Memorandum of Points and Authorities in Opposition to Immotopics' Motion to Declare Case Exceptional Pursuant to 35 U.S.C. § 285 and for Leave to Submit Detailed Description of Attorney Fees, filed on June 15, 2009	
30.	Cantor Response to Zahradnik Notification of Court Decision in Related Litigation, from Patent Interference No. 105,575 (MPT), filed June 23, 2009	
31.	Summons to Attend Oral Proceedings, from an Opposition Against EP Patent No. 1 151 307, dated June 29, 2009	
32.	Final Judgment of Non-Infringement of the '566 Patent in View of the Court's Second Amended Claim Construction Order, filed July 9, 2009	
33.	Court Docket From PACER for Scantibodies Laboratory, Inc. v. Immotopics, Inc., the United States District Court for the Central District of California (Western Division), Case No. CV 04-08871 MRP (MANx), docket accessed July 15, 2009	
34.	Petition Decision from 11/799,726, mailed on June 26, 2009	
35.	Petition Decision from 11/894,367, mailed on June 29, 2009	
36.	Response to Restriction Requirement and Amendment from 11/894,367, filed July 13, 2009	
37.	Statement of Substance of Interview from 10/617,489, filed July 15, 2009	
38.	Statement of Substance of Interview from 10/945,608, filed July 15, 2009	
39.	Non-Final Office Action from 12/286,620, mailed on May 1, 2009	
40.	Response to Office Action from 12/286,620, filed July 1, 2009	
41.	Supplementary European Search Report for EP Application No. 04786049.9 – 2402, mailed on May 11, 2009, 5 pages	
42.	Statement of Substance of Interview from 10/945,608, filed August 13, 2009	
43.	Response to the Summons to Attend Oral Proceedings from an Opposition Against EP Patent No. 1 151 307, dated July 8, 2009 (with English translation)	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/760,091	
			Filing Date	January 16, 2004	
			First Named Inventor	Thomas L. CANTOR	
			Art Unit	1641	
			Examiner Name	C. Cheu	
			Attorney Docket Number	532212000624	
Sheet	3	of	3		

/C.C./	44.	Notice of Intent to Issue Ex Parte Reexamination Certificate from Control No. 90/007,412, mailed on August 14, 2009	
	45.	Office Action from Canadian Patent Application No. 2,360,020, dated July 16, 2009	
	46.	Amendment in Response to Non-Final Office Action from 11/799,726, filed August 31, 2009	
	47.	Memorandum Opinion and Order, Decision on Motions, from Patent Interference No. 105,575 (MPT), filed September 30, 2009	
	48.	Judgment – Bd. R. 127, from Patent Interference No. 105,575 (MPT), filed September 30, 2009	
	49.	Petition Decision from 10/617,489, mailed on August 28, 2009	
	50.	Non-Final Office Action from 11/894,367, mailed on September 25, 2009	
	51.	VEPREK et al., J. Peptide Research (1999) 5:203-220	
	52.	Written Submissions of the Patentee in Respect of Opposition Against EP-B-1151307, filed October 7, 2009, European Patent Office	
	53.	Communication to the European Patent Office from Opposition Against EP-B-1151307, dated October 14, 2009	
	54.	Petition to Withdraw Application From Issue Pursuant to 37 CFR 1.313(c)(2) from 10/945,608, filed October 1, 2009	
	55.	Decision on Petition from 10/945,608, mailed on October 5, 2009	
	56.	Petition to Withdraw Application From Issue Pursuant to 37 CFR 1.313(c)(2) from 10/617,489, filed October 1, 2009	
	57.	Decision on Petition from 10/617,489, mailed on October 5, 2009	
	58.	Brief Communication from EP Opposition Against EP-B-1151307, dated October 14, 2009	
	59.	Brief Communication from EP Opposition Against EP-B-1151307, dated October 15, 2009	
	60.	NonConfidential Brief of Plaintiff-Appellant Scantibodies Laboratory, Inc., filed October 26, 2009, United States Court of Appeals for the Federal Circuit, Case No. 2009-1481	
	61.	Court Docket from PACER for Scantibodies Laboratory, Inc. v. Immunotopics, Inc., currently pending at the United States Court of Appeals for the Federal Circuit, Case No. 2009-1481, docket accessed October 28, 2009	
	62.	Preliminary Amendment from 10/617,489, filed October 27, 2009	
	63.	Office Action from Australian patent application No. 2004266128, dated September 10, 2009	
V	64.	Final Office Action from 11/799,726, mailed on November 2, 2009	

Examiner Signature	/Changhwa Cheu/	Date Considered	01/13/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.